FlashDx Launches New Respiratory and MRSA/SA Panels at MEDICA 2025

FlashDx is introducing two new molecular diagnostic assays at MEDICA 2025—the Respiratory Panel 2 and the MRSA/SA Panel. The launch of these assays further extends FlashDx’s multiplex molecular testing portfolio, reinforcing the company’s commitment to advancing near-patient molecular diagnostics through innovation and automation. FlashDx will also demonstrate its fully automated multiplex molecular diagnostic system, powered by its proprietary sSPRT (semi-Solid Phase Real-Time PCR) technology.

The company is debuting Respiratory Panel 2, which targets additional respiratory pathogens to complement the existing Respiratory Panel 1.1. By broadening organism coverage, the new panel is intended to increase diagnostic flexibility while maintaining a syndromic testing approach. FlashDx is also launching an MRSA/SA Panel for rapid and precise detection of Methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), addressing routine screening and infection control needs in hospitals and clinics.

Image: FlashDx’s proprietary semi-Solid Phase Real Time PCR (sSPRT™) technology enables lab-quality molecular testing in near-patient care settings (Photo courtesy of FlashDx)

FlashDx is demonstrating its sSPRT powered platform at MEDICA 2025. The sSPRT platform enables rapid, accurate, and multiplex pathogen detection within a fully integrated “sample-to-result” workflow, designed to meet the growing needs of infectious disease and reproductive health diagnostics. Built to comply with the EU’s stringent IVD Regulation standards, the system maintains full regulatory integrity without sacrificing speed or flexibility. Its expandable, multi-slot instrumentation provides true random access to a wide range of disease panels and sample types—anytime and anywhere—allowing laboratories to scale testing confidently while meeting global quality and safety requirements

Attendees can meet FlashDx in Hall 3, Booth H26 at MEDICA 2025 to review the new assays and discuss opportunities for collaboration. Founded by U.S. and European industry experts with Silicon Valley know-how, FlashDx offers a turnkey, sample-to-answer platform and a portfolio of syndromic infectious disease cartridges, with plans to expand into oncology and other disease areas.

Related Links:
FlashDx